Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by MetLife Investment Management LLC

MetLife Investment Management LLC increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,532 shares of the medical research company’s stock after acquiring an additional 117 shares during the quarter. MetLife Investment Management LLC’s holdings in Charles River Laboratories International were worth $2,498,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in Charles River Laboratories International during the third quarter worth about $601,000. JPMorgan Chase & Co. increased its stake in shares of Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after purchasing an additional 85,759 shares during the period. Veracity Capital LLC acquired a new stake in shares of Charles River Laboratories International in the fourth quarter valued at approximately $589,000. Lord Abbett & CO. LLC increased its stake in shares of Charles River Laboratories International by 5.8% in the third quarter. Lord Abbett & CO. LLC now owns 108,715 shares of the medical research company’s stock valued at $21,413,000 after purchasing an additional 5,959 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Charles River Laboratories International by 2.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after purchasing an additional 47,221 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Robert W. Baird dropped their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their price target for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Morgan Stanley dropped their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. Mizuho lowered their price objective on shares of Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 9th. Finally, Barclays lowered their price objective on shares of Charles River Laboratories International from $160.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 10th. One analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $182.00.

Insider Activity

In other Charles River Laboratories International news, CEO James C. Foster purchased 6,075 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Birgit Girshick purchased 1,514 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at $9,064,198.54. This trade represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Trading Down 0.9 %

Shares of NYSE CRL opened at $114.71 on Monday. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15. The company has a market cap of $5.63 billion, a price-to-earnings ratio of 764.73, a P/E/G ratio of 4.54 and a beta of 1.45. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The business has a fifty day simple moving average of $146.73 and a 200-day simple moving average of $170.98.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same period in the prior year, the business posted $2.46 earnings per share. Charles River Laboratories International’s revenue was down 1.1% compared to the same quarter last year. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).